Turn Therapeutics Inc. (TTRX) company profile
Close on Nov 17, 2026Market cap $254.69MP/E –Yield –
About Turn Therapeutics
Pharmaceutical Preparations, SIC 2834
Turn Therapeutics Inc. develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections. Its lead investigational drug candidate, GX-03, targets moderate-to-severe eczema and onychomycosis using a polyhexanide formulation. The company also develops medical devices based on this formulation for acute wound management, dermatitis care, and antimicrobial wound dressings. Additionally, it conducts exploratory research on a thermostable intranasal vaccine platform. The company's business model centers on licensing its medical devices to commercial healthcare partners, including Medline and MiMedx, while directing internal resources toward clinical drug development.
The company is based in Westlake Village, California, and is incorporated in Delaware. It operates primarily within the United States, where it conducts clinical trials, while preparing foundational clinical activities in select international jurisdictions. Turn Therapeutics relies on a lean internal workforce alongside third-party contractors, vendors, and commercial distribution partners to carry out its development and manufacturing activities.
Summary of the business section of Turn Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Turn Therapeutics Inc.
- Headquarters
- Westlake Village, CA
- Address
- 250 North Westlake Blvd., #210 91362
- Phone
- (818) 564-4011
- Website
- turntherapeutics.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, Whippany, New Jersey
Stock & identifiers
- Ticker
- TTRX
- Exchange
- Nasdaq
- IPO date
- Oct 8, 2025
- Shares outstanding
- 30M, Aug 12, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2023016
- CUSIP
- 90021W105
- ISIN
- US90021W1053
- FIGI
- BBG002QTLH75
- Share class FIGI
- BBG002QTLH84
- EIN
- 32-0456090
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Bradley Evan Burnam | Chief Executive Officer, Director | 15,416,260 |
| Neilesh Shailesh Ghodadra | Chief Medical Officer, Director | 10,000 |
| Zuraiz Chaudhary | See Remarks | 12,500 |
| Kent Edward Kester | Director | 10,000 |
| Andrew Gengos | Director | 10,000 |
| Martin William Dewhurst | Director | 21,882 |
| Arthur F. Golden | Director | 360,602 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Bradley Burnam Chief Executive Officer | $465.74K | $186.30K | – | $652.04K | +52% |
| Zuraiz Chaudhary Interim Chief Financial Officer | $152.21K | $30.40K | $1.24M | $1.43M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 8, 2025
- Offer price
- $11.65
- Securities offered
- 17,868,760
- Gross proceeds
- $208.17M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Apr 6, 2026
“2025, we commenced an offering of common stock under the exemption from registration provided by Tier 2 of Regulation A under the Securities Act of 1933, as amended (the “Securities Act”) at a public offering price of $11.65 per share, which concluded on June 27, 2025.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 8, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 30, 2025 | Name change | Name changed from Global Health Solutions, Inc to Turn Therapeutics Inc. |
| Sep 29, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?